Since OCTs are important targets for various therapeutic agents, such as metformin or the platinum drugs cisplatin or picoplatin [30,40,41], the finding that SLC22A1 is downregulated in liver cancer due to hypermethylation may be important for alternative therapeutic approaches for treatment of HCC. The gene discussed is SLC22A1; the disease is hepatocellular carcinoma.